Literature DB >> 1524041

Lymphomatoid papulosis: case report of a patient managed with radiation therapy and review of the literature.

T Kaufmann1, L Z Nisce, R T Silver.   

Abstract

Lymphomatoid papulosis is an elusive and very rare skin disorder. It is clinically benign but histologically "atypical," and about 20% of affected patients go on to develop a lymphoreticular malignancy, usually Hodgkin's disease, or mycosis fungoides. A wide variety of treatments to prevent recurrence and improve local control have been suggested, but the results have been poor. We report on a patient with two nonhealing lymphomatoid papulosis lesions treated successfully with electron beam therapy and describe our technique. The need for close follow-up of all patients with this condition cannot be overemphasized.

Entities:  

Mesh:

Year:  1992        PMID: 1524041

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  3 in total

Review 1.  EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.

Authors:  Werner Kempf; Katrin Pfaltz; Maarten H Vermeer; Antonio Cozzio; Pablo L Ortiz-Romero; Martine Bagot; Elise Olsen; Youn H Kim; Reinhard Dummer; Nicola Pimpinelli; Sean Whittaker; Emmilia Hodak; Lorenzo Cerroni; Emilio Berti; Steve Horwitz; H Miles Prince; Joan Guitart; Teresa Estrach; José A Sanches; Madeleine Duvic; Annamari Ranki; Brigitte Dreno; Sonja Ostheeren-Michaelis; Robert Knobler; Gary Wood; Rein Willemze
Journal:  Blood       Date:  2011-08-12       Impact factor: 22.113

Review 2.  A case of lymphomatoid papulosis occurred simultaneously with Ki-1-positive anaplastic large cell lymphoma.

Authors:  N S Lee; S W Cha; S J Hong; W Y Shin; G T Lee; J W Jeon; J H Won; S H Baick; D S Hong; H S Park
Journal:  Korean J Intern Med       Date:  1997-01       Impact factor: 2.884

3.  Single-Fraction Radiotherapy for CD30(+) Lymphoproliferative Disorders.

Authors:  Michelle S Gentile; Maria Estela Martinez-Escala; Tarita O Thomas; Joan Guitart; Steven Rosen; Timothy Kuzel; Bharat B Mittal
Journal:  Biomed Res Int       Date:  2015-10-04       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.